Alvotech (NASDAQ:ALVO) Price Target Cut to $4.00 by Analysts at Barclays

Alvotech (NASDAQ:ALVO) had its price objective lowered by Barclays from $5.00 to $4.00 in a research report released on Tuesday,Benzinga reports. The brokerage currently has an underweight rating on the stock.

A number of other analysts have also commented on the company. Zacks Research raised Alvotech from a “strong sell” rating to a “hold” rating in a research note on Thursday, March 19th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alvotech in a research note on Wednesday, January 21st. Finally, Morgan Stanley set a $10.00 target price on shares of Alvotech in a research report on Wednesday, December 3rd. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $7.60.

Alvotech Stock Performance

NASDAQ ALVO opened at $3.13 on Tuesday. The firm’s fifty day moving average price is $4.46 and its two-hundred day moving average price is $5.77. The stock has a market cap of $943.63 million, a PE ratio of 31.30 and a beta of 0.16. Alvotech has a fifty-two week low of $3.03 and a fifty-two week high of $11.85.

Alvotech (NASDAQ:ALVO) last announced its quarterly earnings results on Wednesday, March 18th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.50). The firm had revenue of $173.20 million during the quarter, compared to the consensus estimate of $162.20 million. Alvotech had a net margin of 4.74% and a negative return on equity of 12.84%. As a group, sell-side analysts predict that Alvotech will post -0.07 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alvotech

Institutional investors and hedge funds have recently made changes to their positions in the business. Goldman Sachs Group Inc. grew its stake in Alvotech by 40.9% during the first quarter. Goldman Sachs Group Inc. now owns 36,444 shares of the company’s stock worth $352,000 after purchasing an additional 10,573 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Alvotech by 0.7% during the 2nd quarter. Geode Capital Management LLC now owns 230,291 shares of the company’s stock worth $2,100,000 after buying an additional 1,574 shares in the last quarter. Legal & General Group Plc boosted its holdings in shares of Alvotech by 17.0% during the 2nd quarter. Legal & General Group Plc now owns 657,742 shares of the company’s stock worth $6,028,000 after buying an additional 95,331 shares in the last quarter. Norges Bank acquired a new stake in shares of Alvotech during the 2nd quarter worth approximately $1,656,000. Finally, Invesco Ltd. grew its position in shares of Alvotech by 37.3% during the 2nd quarter. Invesco Ltd. now owns 32,398 shares of the company’s stock worth $295,000 after buying an additional 8,794 shares during the period.

More Alvotech News

Here are the key news stories impacting Alvotech this week:

• Positive Sentiment: UBS reiterated a Buy on ALVO and cut its price target from $10 to $6, framing regulatory setbacks as largely priced in while pointing to underlying biosimilar strength that supports upside. Article Title
• Positive Sentiment: Coverage pieces highlight Alvotech’s ongoing execution in the biosimilar market and argue for continued growth potential, which could be supportive if revenue trends and margin progress continue. Alvotech Charts Course for Continued Growth in Biosimilar Market
• Positive Sentiment: Northland Securities published commentary on Alvotech’s FY2026 results (revenue beat but EPS miss in recent quarter), providing additional analyst attention that may help reprice the stock as investors parse forward guidance and pipeline milestones. Northland Securities Comments on Alvotech FY2026 Earnings
• Neutral Sentiment: Short-interest reports are inconsistent: one clean print shows a meaningful decline to ~2.46M shares short (≈0.8% of shares) as of March 13 with a short-interest ratio ~3.7 days — a modest short base. However, multiple March 23–24 data entries report “0 shares” (likely reporting glitches), so short-interest trends should be treated cautiously.
• Negative Sentiment: Barclays cut its price target from $5 to $4 and maintained an Underweight rating, a bearish signal that likely pressured the stock alongside broader downgrades. Article Title
• Negative Sentiment: Analyst target reductions overall (UBS lowered its PT despite keeping a Buy; Barclays trimmed target and kept Underweight) increase near-term uncertainty and likely contributed to the share decline as investors weigh regulatory risk, earnings misses, and execution against long-term biosimilar opportunity. Alvotech: Regulatory Setbacks Priced In…

About Alvotech

Alvotech (NASDAQ:ALVO) is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).